Despite the availability of the human papillomavirus (HPV) vaccine, cervical cancer remains a significant problem in the United States and worldwide.1 Furthermore, the treatment of recurrent or metastatic disease continues to pose even more of a challenge to clinicians. At the NCCN 2023 Annual Conference, Nadeem R. Abu-Rustum, MD, Chief, Gynecology Service; Avon Chair in Gynecologic Oncology Research, Memorial Sloan Kettering Cancer Center; Professor, Weill Cornell Medical College; and Chair of the NCCN Guidelines Panel for Cervical Cancer discussed significant advances in surgery, radiation therapy (RT), and chemotherapy for cervical cancer, as well as treatment limitations for this disease.
Brader KR, Morris M, Levenback C, et al. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol 1998;16:1879–1884.
Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 1.2023. Accessed April 4, 2023. To view the most recent version, visit https://www.nccn.org
Pang SS, Murphy M, Markham MJ. Current management of locally advanced and metastatic cervical cancer in the United States. JCO Oncol Pract 2022;18:417–422.
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 2021;385:1856–1867.